{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T12:44:11Z","timestamp":1791636251796,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.neurot.2025.e00554","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T04:55:19Z","timestamp":1740027319000},"page":"e00554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Extended-interval dosing of rituximab\/ocrelizumab is associated with a reduced decrease in IgG levels in multiple sclerosis"],"prefix":"10.1016","volume":"22","author":[{"given":"Camille","family":"Rigollet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean A.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Perriguey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Patrick","family":"Stellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Graille-Avy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Lafontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Lemarchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tifanie","family":"Alberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Demorti\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Boutiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Rico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Hil\u00e9zian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Durozard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Maarouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Z\u00e9phir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Audoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.neurot.2025.e00554_bib1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00554_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2023-333206","article-title":"Impact of previous treatment history and B-cell depletion treatment duration on infection risk in relapsing-remitting multiple sclerosis: a nationwide cohort study","author":"Virtanen","year":"2024","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00554_bib3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/jnnp-2022-330100","article-title":"SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis","volume":"94","author":"van Kempen","year":"2023","journal-title":"J\u00a0Neurol Neurosurg Psychiatry. avr"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00554_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.19766","article-title":"Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis","volume":"6","author":"Januel","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00554_bib5","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.26028","article-title":"Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis","volume":"89","author":"Sormani","year":"2021","journal-title":"Ann Neurol. avr"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00554_bib6","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/acn3.51136","article-title":"Serious safety events in rituximab-treated multiple sclerosis and related disorders","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00554_bib7","doi-asserted-by":"crossref","first-page":"e1115","DOI":"10.1212\/NXI.0000000000001115","article-title":"Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with rituximab","volume":"9","author":"Perriguey","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurot.2025.e00554_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104400","article-title":"Infection risk in a real-world cohort of patients treated with long-term B-cell depletion for autoimmune neurologic disease","volume":"68","author":"Peters","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2025.e00554_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105009","article-title":"Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management","volume":"79","author":"Alvarez","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00554_bib10","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200211","article-title":"Multiple sclerosis, rituximab, hypogamma-globulinemia, and risk of infections","volume":"11","author":"Langer-Gould","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurot.2025.e00554_bib11","article-title":"Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: a Swedish cohort study","volume":"25","author":"Hallberg","year":"2024","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00554_bib12","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200056","article-title":"Sustained low relapse rate with highly variable B-cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis","volume":"10","author":"Starvaggi Cucuzza","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00554_bib13","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1212\/NXI.0000000000000825","article-title":"Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?","volume":"7","author":"Maarouf","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00554_bib14","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200152","article-title":"Efficacy of rituximab outlasts B-cell repopulation in multiple sclerosis: time to rethink dosing?","volume":"10","author":"Claverie","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00554_bib15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/13524585231223069","article-title":"Control of disease activity with large extended-interval dosing of rituximab\/ocrelizumab in highly active pediatric multiple sclerosis","volume":"30","author":"Venet","year":"2024","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00554_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/13524585241245296","article-title":"Extended interval dosing with ocrelizumab in multiple sclerosis","author":"Novak","year":"2024","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00554_bib17","article-title":"Memory B cell-guided extended interval dosing of ocrelizumab in multiple sclerosis","volume":"20","author":"Meng","year":"2024","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00554_bib18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585231208311","article-title":"Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity","volume":"30","author":"Bou","year":"2024","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00554_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105028","article-title":"Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing - similar clinical efficacy with decreased immunoglobulin M deficiency rates","volume":"79","author":"Rempe","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00554_bib20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12974-023-02900-z","article-title":"Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis","volume":"20","author":"Rodriguez-Mogeda","year":"2023","journal-title":"J\u00a0Neuroinflammation"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00554_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/ene.15891","article-title":"Ocrelizumab\u00a0extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience","volume":"30","author":"Guerrieri","year":"2023","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00554_bib22","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s13311-022-01289-6","article-title":"Is it time for ocrelizumab extended interval dosing in relapsing remitting MS? Evidence from an Italian multicenter experience during the COVID-19 pandemic","volume":"19","author":"Zangh\u00ec","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00554_bib23","doi-asserted-by":"crossref","first-page":"e1035","DOI":"10.1212\/NXI.0000000000001035","article-title":"Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19","volume":"8","author":"Rolfes","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00554_bib24","article-title":"Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis","volume":"4","author":"Schuckmann","year":"2023","journal-title":"M\u00e9dica Sur"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00554_bib25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00554_bib26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00554_bib27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N\u00a0Engl J Med"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T13:26:19Z","timestamp":1744723579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925000327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1878747925000327"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00554","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended-interval dosing of rituximab\/ocrelizumab is associated with a reduced decrease in IgG levels in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00554","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00554"}}